286 related articles for article (PubMed ID: 17311308)
41. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
42. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.
Danilkovitch-Miagkova A; Leonard EJ
Histol Histopathol; 2001 Apr; 16(2):623-31. PubMed ID: 11332718
[TBL] [Abstract][Full Text] [Related]
43. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
[TBL] [Abstract][Full Text] [Related]
44. Human RON receptor tyrosine kinase induces complete epithelial-to-mesenchymal transition but causes cellular senescence.
Côté M; Miller AD; Liu SL
Biochem Biophys Res Commun; 2007 Aug; 360(1):219-25. PubMed ID: 17588532
[TBL] [Abstract][Full Text] [Related]
45. β-Catenin is required for Ron receptor-induced mammary tumorigenesis.
Wagh PK; Gray JK; Zinser GM; Vasiliauskas J; James L; Monga SP; Waltz SE
Oncogene; 2011 Aug; 30(34):3694-704. PubMed ID: 21423209
[TBL] [Abstract][Full Text] [Related]
46. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
47. Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells.
Wang D; Shen Q; Xu XM; Chen YQ; Wang MH
Carcinogenesis; 2005 Jan; 26(1):27-36. PubMed ID: 15447977
[TBL] [Abstract][Full Text] [Related]
48. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
49. (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC‑1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Kim SO; Kim MR
Int J Oncol; 2013 Jan; 42(1):349-58. PubMed ID: 23135610
[TBL] [Abstract][Full Text] [Related]
50. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer.
Song YA; Park YL; Kim KY; Myung E; Chung CY; Cho SB; Lee WS; Jung YD; Kweon SS; Joo YE
Pathol Int; 2012 Feb; 62(2):127-36. PubMed ID: 22243783
[TBL] [Abstract][Full Text] [Related]
51. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression.
Usami Y; Satake S; Nakayama F; Matsumoto M; Ohnuma K; Komori T; Semba S; Ito A; Yokozaki H
J Pathol; 2008 Jul; 215(3):330-9. PubMed ID: 18491351
[TBL] [Abstract][Full Text] [Related]
52. [Study of RON mediated invasion of Raji cell line and drug-target effects].
Zhan BC; Dong YH; Fan J; Yao HP; Jin J; Tong XM
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):926-30. PubMed ID: 24294846
[TBL] [Abstract][Full Text] [Related]
53. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
54. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
[TBL] [Abstract][Full Text] [Related]
55. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation.
Ellenrieder V; Hendler SF; Boeck W; Seufferlein T; Menke A; Ruhland C; Adler G; Gress TM
Cancer Res; 2001 May; 61(10):4222-8. PubMed ID: 11358848
[TBL] [Abstract][Full Text] [Related]
56. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
57. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells.
Zhang K; Zhou YQ; Yao HP; Wang MH
Int J Oncol; 2010 Jan; 36(1):255-64. PubMed ID: 19956854
[TBL] [Abstract][Full Text] [Related]
58. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
Lu Y; Yao HP; Wang MH
J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
[TBL] [Abstract][Full Text] [Related]
59. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
Yao HP; Hudson R; Wang MH
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
[TBL] [Abstract][Full Text] [Related]
60. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
